Hostname: page-component-7b7567c8c-2n9c9 Total loading time: 0 Render date: 2026-11-14T08:15:02.060Z Has data issue: false hasContentIssue false

The safety dance: biophysics of membrane protein folding and misfolding in a cellular context

Published online by Cambridge University Press:  25 November 2014

Jonathan P. Schlebach
Affiliation:
Department of Biochemistry and Center for Structural Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
Charles R. Sanders*
Affiliation:
Department of Biochemistry and Center for Structural Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
*
*Author for correspondence: C. R. Sanders, Department of Biochemistry and Center for Structural Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA. Phone: 615-936-3756; Fax: 615-936-2211; Email: chuck.sanders@vanderbilt.edu
Rights & Permissions [Opens in a new window]

Abstract

Most biological processes require the production and degradation of proteins, a task that weighs heavily on the cell. Mutations that compromise the conformational stability of proteins place both specific and general burdens on cellular protein homeostasis (proteostasis) in ways that contribute to numerous diseases. Efforts to elucidate the chain of molecular events responsible for diseases of protein folding address one of the foremost challenges in biomedical science. However, relatively little is known about the processes by which mutations prompt the misfolding of α-helical membrane proteins, which rely on an intricate network of cellular machinery to acquire and maintain their functional structures within cellular membranes. In this review, we summarize the current understanding of the physical principles that guide membrane protein biogenesis and folding in the context of mammalian cells. Additionally, we explore how pathogenic mutations that influence biogenesis may differ from those that disrupt folding and assembly, as well as how this may relate to disease mechanisms and therapeutic intervention. These perspectives indicate an imperative for the use of information from structural, cellular, and biochemical studies of membrane proteins in the design of novel therapeutics and in personalized medicine.

Information

Type
Review Article
Copyright
Copyright © Cambridge University Press 2014 
Figure 0

Fig. 1.Folding and misfolding of α-helical membrane proteins. Membrane protein biosynthesis involves several coupled processes, which are vulnerable to the influence of pathogenic mutations. (a) A cartoon depicts a typical biosynthetic pathway for an α-helical membrane protein. Biosynthesis begins with cotranslational integration of nascent α-helices (red) into the membrane (gray bar) by the translocon (gray donut), which is accompanied by early folding events (I). The nascent membrane protein (yellow) is released into the ER membrane following synthesis, where folding may continue with assistance of chaperones and folding enzymes (II). Once the protein achieves its native fold (green), it may form oligomeric complexes with potential interaction partners (blue) (III) prior to export from the ER. (b) Pathogenic mutations (red circle) may cause misincorporation of TM helices by the translocon, which establishes an incorrect topology for the nascent protein. (c) Pathogenic mutations may disfavor the formation of native tertiary or quaternary interactions. (d) Mutations may favor the formation of non-native contacts and/or aggregate formation. Here, we illustrate one of many possibilities, where the mutation both destabilizes the monomer structure and promotes formation of a non-native heterodimer.

Figure 1

Fig. 2.Structure of the translocon. (a) A surface representation of the structure of the Pyrococus furiousus SecYEβ translocon in an open conformation (PDB code 3MP7) is shown. A yellow circle indicates the position of the protein conducting channel. The membrane is indicated in blue. (b) A cross-section of the structure reveals that the protein conducting pore is lined with both apolar and polar side chains. (c) A top down view depicts the opening of the lateral gate, through which nascent TM helices may access the ER membrane. (Figure from Öjemalm et al. 2011).

Figure 2

Fig. 3.Steric trap method originally developed by Heedeok Hong and James Bowie to assess the conformational equilibria of a membrane protein by measuring interactions between biotinylated membrane proteins and engineered monovalent streptavidins (mSA). Biotin labels are introduced at two proximal sites in the native conformation of the protein of interest (black circles). Binding of a single mSA to one of the biotins attached to the folded membrane protein occurs with high affinity. Binding of a second mSA to the other biotin can take place only after the membrane protein spontaneously unfolds. Unfolding and binding of this second mSA are therefore thermodynamically coupled. The position of the equilibrium between the single mSA-bound folded protein and the mSA-double bound unfolded form is assessed as a function of mSA concentration using any one of a variety of possible methods (unfolding-induced dissociation of a fluorescent excimer pair is implied in this example). Changes in the observed signal as a function of [mSA] can be fit for the equilibrium constant for unfolding (Kunfold) by accounting for the known binding affinity of mSA for avidin. This method relies on use of an engineered series of mSA with Kd,avidin spanning several orders of magnitude. Choice of the optimal engineered mSA to use is based on the need to tune the balance between the binding and unfolding equilibria.

Figure 3

Fig. 4.Topology of human PMP22 and distribution of pathogenic missense-encoded single amino acid mutations within its sequence. Residues for which pathogenic variants have been identified are indicated in red, and the identities of the pathogenic side-chain substitutions are indicated. Mutations in PMP22 result in Charcot–Marie–Tooth disease and related disorders.

Figure 4

Fig. 5.Folding and conformational dynamics of human PMP22. (a) WT PMP22 was equilibrated in mixed micelles containing DPC in the absence (diamonds) and presence (circles) of 15% glycerol and varying levels of the denaturing detergent lauroyl sarcosine (LS). For each point tertiary structural content was monitored using the near-UV circular dichroism signal at 299 nm ([θ]299). Closed symbols are for a forward titration (unfolding) with LS. Open symbols are for a reverse (refolding) titration. The match between the forward and reverse titration data indicates the complete reversibility of the unfolding/refolding transitions, as confirmed by complementary kinetic studies (Schlebach et al. 2013). Kinetic and thermodynamic analyses suggest that the fraction of folded PMP22 in the absence of 15% glycerol (diamonds) is close to 0·5 in DPC micelles in the absence of LS (ΔGunf ≈ 0 kcal mol−1). PMP22 is stabilized in the presence of 15% glycerol, which shifts the unfolding transition to higher mole fractions of denaturing detergent under this condition (circles). However, a fit of the unfolding transition to a two-state equilibrium model (black line) suggests that the folded conformation is still only marginally favored in the presence of glycerol (ΔGunf = 1·5 ± 0·1 kcal mol−1). (Figure from Schlebach et al. 2013) (b) The structural dynamics of WT and L16P PMP22 were assessed in tetradecylphosphocholine (TDPC) micelles using solution NMR and other methods. The results indicate that the initial state of PMP22 unfolding involves dissociation of its first TM segment from the four-helix bundle, with the remaining three-helix bundle adopting a molten globule-like state in the membrane. The pathogenic L16P mutation breaks the first TM segment and shifts the folding equilibrium towards the partially unfolded state. (Modified figure from Sakakura et al. 2011).

Figure 5

Fig. 6.ER quality control in eukaryotic cells. This diagram depicts the interplay between the ERAF and ERAD pathways within the pathway of membrane protein biosynthesis, folding, and trafficking. Nascent α-helical membrane proteins are cotranslationally inserted into the ER membrane as they come off the ribosome. The proteins then engage in quality control through numerous interactions with chaperones and folding sensors in the ERAF pathway. Nascent proteins that pass quality control are eventually exported to their destination membranes by way of the Golgi apparatus. Proteins that fail to achieve their native fold are eventually extruded from the ER membrane into the cytoplasm and polyubiquitinated. These proteins are ultimately disposed of by proteasomes or form aggregates that may be degraded or might ultimately elicit cellular toxicity.

Figure 6

Fig. 7.Finite capacity of cellular quality control. The trans-effects of protein misfolding were examined using genetically modified Caenorhabditis elegans. Fluorescence images are shown of larvae carrying one (Q40 m het, a) or two (Q40 m, b) copies of a fluorescently-labelled, aggregation-prone polyglutamine repeat protein at permissive growth temperatures. Images are also shown of Q40 m larvae carrying temperature-sensitive mutations in the ras (c) and paramyosin (d) proteins grown at permissive temperatures. (e) Quantification of visible polyglutamine aggregates in these organisms demonstrates that the expression of other unstable proteins (i.e. mutant ras or paramyosin) can prompt the aggregation of an otherwise soluble protein (Q40 m), presumably due to competition between the two proteins for shared components of the ERAF pathway (Figure from Gidalevitz et al. 2006).

Figure 7

Fig. 8.Physical chemistry of folding and export. (a) A schematic illustration of a simplified model for FoldEx of nascent proteins from the ER. Secreted proteins are synthesized by the translocon (T), and the nascent protein (U) either productively forms the native conformation (F) (pathway 8), or is entered into a chaperone (C) binding cycle (pathway 3). Hydrolysis of ATP is coupled to conformational changes that release the nascent protein (pathways 5 and 6) in order to enable productive folding (pathway 8) or misfolding (pathway 13). Proteins that achieve the native fold are recognized by the export machinery (E) and exported from the ER (pathways 9 and 10). However, proteins that misfold or fail to fold quickly are either reengaged by chaperones (pathways 7 and 14) or are recognized by the retrotranslocon machinery (pathways 11 and 15) and targeted for degradation. Simplification of the relevant interactions using Michaelis–Menten formalism and estimation of relevant rate constants (summarized in box) recapitulates the observed relationships between the conformational stability and export of TTR and BPTI. (Figure from Wiseman et al. 2007b) (b) Simplification of the FoldEx model suggests that cell-specific expression and activities associated with ERAD and ERAF components are capable of handling proteins (different proteins represented by green) with permissible combinations of thermodynamic stability, folding rates, and misfolding rates as indicated by the cellular proteostasis boundary (purple). Proteins that fall within the proteostasis boundary are produced and degraded normally. However, destabilized variants (red) may breach this boundary (left), which can lead to the saturation of quality control and pathogenic misfolding. Because folding and export hinge on protein–protein interactions (connecting lines), destabilized variants may either directly destabilize interaction partners or indirectly destabilize competing quality control substrates (right). The destabilized variant and its interaction partners may then saturate quality control, prompt pathogenic misfolding, and induce cellular stress (Figure from Powers et al. 2009).

Figure 8

Fig. 9.Potential influence of membrane curvature and lipid composition on the conformational equilibrium of α-helical membrane proteins. A given membrane protein may experience a variety of different membrane curvatures and lipid compositions as it traffics through the membranes of various organelles and transport vesicles. Cartoons depict the potential influences of membrane curvature and cholesterol content on protein stability. (a) For this hypothetical membrane protein the native conformation (green) is favored over unfolded conformations (yellow) in membranes with positive curvature. (Other membrane proteins may have the opposite preference.) (b) For this same hypothetical protein, negative membrane curvature destabilizes the native conformation relative to unfolded conformations. (c) For this hypothetical protein the native conformation is favored in membranes containing high concentrations of cholesterol and is less stable in membranes than contain lower cholesterol (d). (Other membrane proteins may exhibit an opposite trend.)

Figure 9

Fig. 10.Influence of pharmacological chaperones on the conformational equilibrium of multi-pass α-helical membrane proteins. (a) Scheme depicting the influence of pharmacological chaperones on the folding of nascent multi-pass α-helical membrane proteins. Nascent proteins are initially inserted into the ER membrane, where they assume a partially folded intermediate ensemble. Funneling of these intermediate ensembles through the biological folding pathway results in the formation of the correctly folded protein, which is competent for export from the ER. However, failure to do so in an efficient or timely manner may lead to a loss of the nascent protein through the ERAD pathway. The kinetics and thermodynamic of the folding transition are sensitive to the influence of pharmacological chaperones, which selectively stabilize the native conformation and/or the rate limiting transition state for folding. (b) The partitioning of the nascent protein between folding and ERAD is illustrated with an energy diagram. Unfolded conformations of nascent wild-type membrane protein (yellow) kinetically partition between the folding pathway and the ERAD pathway. Nascent proteins must overcome a rate-limiting energy barrier for folding (‡) to achieve the native conformation (green) prior to recognition by components of the ERAD pathway. (c) The incorporation of a pathogenic mutation within a TM helix (red circle) destabilizes the native conformation and/or the rate-limiting transition state for folding, which decreases the rate and efficiency of folding of the mutant protein. The effects of the mutation (red) may be partially offset in the presence of a pharmacological chaperone (blue) that preferentially binds and stabilizes the native conformation and/or the rate-limiting transition state for folding. (d) Pathogenic variants with incorrect topologies may be kinetically isolated from the native folding pathway. Reorientation of the TM helices with respect to the membrane may be outpaced by the association of the nascent protein with ERAD components. Thus, the influence of pharmacological chaperones on the conformational energy landscapes may be insufficient to rescue nascent membrane proteins with aberrant topologies.